115 related articles for article (PubMed ID: 24433863)
21. The use of spirocyclic scaffolds in drug discovery.
Zheng Y; Tice CM; Singh SB
Bioorg Med Chem Lett; 2014 Aug; 24(16):3673-82. PubMed ID: 25052427
[TBL] [Abstract][Full Text] [Related]
22. Synthesis, SAR study, and biological evaluation of a series of piperazine ureas as fatty acid amide hydrolase (FAAH) inhibitors.
Kono M; Matsumoto T; Kawamura T; Nishimura A; Kiyota Y; Oki H; Miyazaki J; Igaki S; Behnke CA; Shimojo M; Kori M
Bioorg Med Chem; 2013 Jan; 21(1):28-41. PubMed ID: 23218778
[TBL] [Abstract][Full Text] [Related]
23. The fatty acid amide hydrolase inhibitor URB597 (cyclohexylcarbamic acid 3'-carbamoylbiphenyl-3-yl ester) reduces neuropathic pain after oral administration in mice.
Russo R; Loverme J; La Rana G; Compton TR; Parrott J; Duranti A; Tontini A; Mor M; Tarzia G; Calignano A; Piomelli D
J Pharmacol Exp Ther; 2007 Jul; 322(1):236-42. PubMed ID: 17412883
[TBL] [Abstract][Full Text] [Related]
24. Cyclohexylcarbamic acid 3'- or 4'-substituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: synthesis, quantitative structure-activity relationships, and molecular modeling studies.
Mor M; Rivara S; Lodola A; Plazzi PV; Tarzia G; Duranti A; Tontini A; Piersanti G; Kathuria S; Piomelli D
J Med Chem; 2004 Oct; 47(21):4998-5008. PubMed ID: 15456244
[TBL] [Abstract][Full Text] [Related]
25. Synthesis of Multifunctional Spirocyclic Azetidines and Their Application in Drug Discovery.
Kirichok AA; Shton IO; Pishel IM; Zozulya SA; Borysko PO; Kubyshkin V; Zaporozhets OA; Tolmachev AA; Mykhailiuk PK
Chemistry; 2018 Apr; 24(21):5444-5449. PubMed ID: 29338097
[TBL] [Abstract][Full Text] [Related]
26. Trianion synthon approach to spirocyclic heterocycles.
Perry MA; Hill RR; Rychnovsky SD
Org Lett; 2013 May; 15(9):2226-9. PubMed ID: 23594129
[TBL] [Abstract][Full Text] [Related]
27. 1-Aryl-2-((6-aryl)pyrimidin-4-yl)amino)ethanols as competitive inhibitors of fatty acid amide hydrolase.
Keith JM; Hawryluk N; Apodaca RL; Chambers A; Pierce JM; Seierstad M; Palmer JA; Webb M; Karbarz MJ; Scott BP; Wilson SJ; Luo L; Wennerholm ML; Chang L; Rizzolio M; Chaplan SR; Breitenbucher JG
Bioorg Med Chem Lett; 2014 Mar; 24(5):1280-4. PubMed ID: 24513048
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of fatty acid amide hydrolase and cyclooxygenase by the N-(3-methylpyridin-2-yl)amide derivatives of flurbiprofen and naproxen.
Cipriano M; Björklund E; Wilson AA; Congiu C; Onnis V; Fowler CJ
Eur J Pharmacol; 2013 Nov; 720(1-3):383-90. PubMed ID: 24120370
[TBL] [Abstract][Full Text] [Related]
29. Fatty acid amide hydrolase inhibitors display broad selectivity and inhibit multiple carboxylesterases as off-targets.
Zhang D; Saraf A; Kolasa T; Bhatia P; Zheng GZ; Patel M; Lannoye GS; Richardson P; Stewart A; Rogers JC; Brioni JD; Surowy CS
Neuropharmacology; 2007 Mar; 52(4):1095-105. PubMed ID: 17217969
[TBL] [Abstract][Full Text] [Related]
30. Reversible competitive α-ketoheterocycle inhibitors of fatty acid amide hydrolase containing additional conformational constraints in the acyl side chain: orally active, long-acting analgesics.
Ezzili C; Mileni M; McGlinchey N; Long JZ; Kinsey SG; Hochstatter DG; Stevens RC; Lichtman AH; Cravatt BF; Bilsky EJ; Boger DL
J Med Chem; 2011 Apr; 54(8):2805-22. PubMed ID: 21428410
[TBL] [Abstract][Full Text] [Related]
31. Structure activity relationships of fused bicyclic and urea derivatives of spirocyclic compounds as potent CCR1 antagonists.
Hossain N; Mensonides-Harsema M; Cooper ME; Eriksson T; Ivanova S; Bergström L
Bioorg Med Chem Lett; 2014 Jan; 24(1):108-12. PubMed ID: 24332486
[TBL] [Abstract][Full Text] [Related]
32. Benzothiophene piperazine and piperidine urea inhibitors of fatty acid amide hydrolase (FAAH).
Johnson DS; Ahn K; Kesten S; Lazerwith SE; Song Y; Morris M; Fay L; Gregory T; Stiff C; Dunbar JB; Liimatta M; Beidler D; Smith S; Nomanbhoy TK; Cravatt BF
Bioorg Med Chem Lett; 2009 May; 19(10):2865-9. PubMed ID: 19386497
[TBL] [Abstract][Full Text] [Related]
33. Oxidative 1,4-diamination of dienes using simple urea derivatives.
Anumandla D; Littlefield R; Jeffrey CS
Org Lett; 2014 Oct; 16(19):5112-5. PubMed ID: 25215513
[TBL] [Abstract][Full Text] [Related]
34. Synthesis and biological evaluation of piperazinyl carbamates and ureas as fatty acid amide hydrolase (FAAH) and transient receptor potential (TRP) channel dual ligands.
Morera E; De Petrocellis L; Morera L; Moriello AS; Ligresti A; Nalli M; Woodward DF; Di Marzo V; Ortar G
Bioorg Med Chem Lett; 2009 Dec; 19(23):6806-9. PubMed ID: 19875281
[TBL] [Abstract][Full Text] [Related]
35. Heterocyclic sulfoxide and sulfone inhibitors of fatty acid amide hydrolase.
Du W; Hardouin C; Cheng H; Hwang I; Boger DL
Bioorg Med Chem Lett; 2005 Jan; 15(1):103-6. PubMed ID: 15582420
[TBL] [Abstract][Full Text] [Related]
36. Covalent inhibitors of fatty acid amide hydrolase: a rationale for the activity of piperidine and piperazine aryl ureas.
Palermo G; Branduardi D; Masetti M; Lodola A; Mor M; Piomelli D; Cavalli A; De Vivo M
J Med Chem; 2011 Oct; 54(19):6612-23. PubMed ID: 21830831
[TBL] [Abstract][Full Text] [Related]
37. Blocking of fatty acid amide hydrolase activity with PF-04457845 in human brain: a positron emission tomography study with the novel radioligand [(11)C]CURB.
Boileau I; Rusjan PM; Williams B; Mansouri E; Mizrahi R; De Luca V; Johnson DS; Wilson AA; Houle S; Kish SJ; Tong J
J Cereb Blood Flow Metab; 2015 Nov; 35(11):1827-35. PubMed ID: 26082009
[TBL] [Abstract][Full Text] [Related]
38. Fatty acid amide hydrolase (FAAH) inhibition reduces L-3,4-dihydroxyphenylalanine-induced hyperactivity in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned non-human primate model of Parkinson's disease.
Johnston TH; Huot P; Fox SH; Wakefield JD; Sykes KA; Bartolini WP; Milne GT; Pearson JP; Brotchie JM
J Pharmacol Exp Ther; 2011 Feb; 336(2):423-30. PubMed ID: 20966038
[TBL] [Abstract][Full Text] [Related]
39. Discovery and molecular basis of potent noncovalent inhibitors of fatty acid amide hydrolase (FAAH).
Min X; Thibault ST; Porter AC; Gustin DJ; Carlson TJ; Xu H; Lindstrom M; Xu G; Uyeda C; Ma Z; Li Y; Kayser F; Walker NP; Wang Z
Proc Natl Acad Sci U S A; 2011 May; 108(18):7379-84. PubMed ID: 21502526
[TBL] [Abstract][Full Text] [Related]
40. High-throughput screening for the discovery of inhibitors of fatty acid amide hydrolase using a microsome-based fluorescent assay.
Wang Y; Ramirez F; Krishnamurthy G; Gilbert A; Kadakia N; Xu J; Kalgaonkar G; Ramarao MK; Edris W; Rogers KE; Jones PG
J Biomol Screen; 2006 Aug; 11(5):519-27. PubMed ID: 16760367
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
